Aussie Institute Urges Coverage Of Osteoporosis Drugs For Breast Cancer
This article was originally published in PharmAsia News
Executive Summary
Health experts in Australia are calling on the government to cover the use of osteoporosis drugs for women with a high risk of breast cancer. The New South Wales Cancer Institute cited international trials that have demonstrated tamoxifen and raloxifene are effective in preventing breast cancer. The head of the institute said Australia's Pharmaceutical Benefits Scheme should place both drugs on its formulary even though they would cost the government $187.7 million. He said the expenditure would be cost-effective in the long run. (Click here for more
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.